HaluGen Life Sciences’ test evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy Vancouver, British Columbia–(Newsfile Corp. – June 10, 2021) – Entheon...
Vancouver, British Columbia–(Newsfile Corp. – May 18, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused...
Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened...
Vancouver, British Columbia–(Newsfile Corp. – May 5, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) (“Entheon” or the “Company“), a biotechnology company focused...
HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical...
Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Microdose Psychedelic Insights (“Microdose”), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund, the most...
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins...
Completion of research and development phase for HaluGen’s Psychedelics Genetic Test Vancouver, British Columbia–(Newsfile Corp. – February 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE:...
Vancouver, British Columbia–(Newsfile Corp. – February 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused...
Vancouver, British Columbia–(Newsfile Corp. – February 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company...